-
s Novel 2,4- diaminopyrimidine 5-carboxamides as c-Jun N-terminal Kinase Inhibitors for Treating the Liver Fibrotic Disorder
- Source: Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Volume 23, Issue 8, Jul 2023, p. 1118 - 1123
-
- 01 Jul 2023
- Previous Article
- Table of Contents
- Next Article
Abstract
Diaminopyrimidine compounds having the following general structure (I), compositions comprising an effective amount of a diaminopyrimidine compound, and methods for treating or preventing fibrotic liver disorders or other diseases associated with the JNK pathway are discussed in this patent study.
© Bentham Science Publishers